Skip to main content
NewslettersWatchlist

Medmira Inc(MIR-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.080
Day High0.080
Open:0.080
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
ACCESSWIRE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
ACCESSWIRE
Progress Update on Securities
ACCESSWIRE
MedMira Reports Third Quarter Results FY2023
ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
ACCESSWIRE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
Business Wire
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
ACCESSWIRE
MedMira Enters into Partnership with Maternova for USA and Latin America
ACCESSWIRE
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
ACCESSWIRE
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
ACCESSWIRE
MedMira Reports First Quarter Results FY2023
ACCESSWIRE
MedMira Introduces VYRA TriDemic
ACCESSWIRE
MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
ACCESSWIRE
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
Globe Newswire
MedMira Strengthens and Expands Board
Globe Newswire
MedMira Reports Third Quarter Results FY2022
Globe Newswire
MedMira Receives Patent for its Unique Quantitative Diagnostic System
Globe Newswire
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
Globe Newswire
VYRA™ Product Line Update
Globe Newswire
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
Globe Newswire
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
Globe Newswire
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

Profile

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.